The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer
Official Title: A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC
Study ID: NCT02470468
Brief Summary: The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).
Detailed Description: The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. Standard of Care chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Brno, , Czechia
, Hradec Kralove, , Czechia
, Jindřichův Hradec, , Czechia
, Kutna Hora, , Czechia
, Nachod, , Czechia
, Olomouc, , Czechia
, Ostrava, , Czechia
, Pardubice, , Czechia
, Plzen, , Czechia
, Praha, , Czechia
, Praha, , Czechia
, Praha, , Czechia
, Pribram, , Czechia
, Usti nad Labem, , Czechia
, Zlin, , Czechia
, Kosice, , Slovakia
, Piest'any, , Slovakia
, Poprad, , Slovakia
Name: Tomas Scheiner
Affiliation: Sotio Biotech Inc.
Role: STUDY_DIRECTOR